Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Existing Biologic Antitumor Agents
- Monoclonal Antibodies
- Rituxan
- Herceptin
- Avastin
- Recombinant Cytokines
- Targeted Cytotoxins and Radiological Agents
- Emerging Antitumor Biologics
- Panitumumab
- Pertuzumab
- Galiximab
- Volociximab
- Mapatumumab
- CAT-3888
- CDP-791
- Herceptin: A Model for Expanding an Agent' s Reach
- Reimbursement Concerns with Anticancer Biologics
- Outlook
Tables
- 1. Select Antitumor Biologic Therapeutic Approaches
- 2. Current Antitumor Protein Drugs, 2006
- 3. Select Emerging Antitumor Biologic Agents, 2006
- 4. Early Stage Approaches to Biological Cancer Treatment
- 5. Critical Clinical Trial Results for Herceptin
Figures
- 1. Antibody Structure
- 2. Number of Anticancer Biologics on the Market, 1995-2006
|
Related Report
|
View Cart
